META-ANALYSIS REINFORCES VALUE OF WARFARIN AND ANTIPLATELET AGENTS

SEPTEMBER 01, 2007
Anna D. Garrett, PharmD, BCPS, CPP

A recently updated meta-analysis of patients with atrial fibrillation reinforced the value of warfarin and antiplatelet agents for stroke prevention in this population. Twentynine trials were studied, 13 of which were new since the authors last conducted a similar analysis. More than 28,000 participants were included from the various studies. Adjusted-dose warfarin reduced stroke by approximately 60%, while antiplatelet agents reduced the risk by 20%. Adjusted-dose warfarin doubled the risk for major bleeding events, but the absolute number of these events amounted to only 0.2% per year. The authors concluded that antithrombotic therapy, when used carefully, provides important decreases in the risk of stroke for patients with atrial fibrillation.



SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.